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Abstract: Bacterial vaginosis (BV) is the commonest cause of vaginal discharge in women 
of childbearing age. Oral metronidazole has long been established as an effective therapy in 
the treatment of BV. However, adverse effects due to metronidazole are frequent and this may 
lead to problems with adherence to a 7-day course of treatment and subsequently result in treat-
ment failure. Oral tinidazole has been used to treat bacterial vaginosis for over 25 years but 
in a number of different dosage regimens. Placebo controlled trials have consistently shown 
increases in cure rate with tinidazole. Longer courses of treatment (eg, 1 g daily for 5 days) 
appear to be more effective than a 2 g oral single dose. Comparative studies suggest that oral 
tinidazole is equivalent to oral metronidazole, intravaginal clindamycin cream, and intravaginal 
metronidazole tablets, in efficacy in treating BV. However, tinidazole has a more favorable 
side effect profile than oral metronidazole notably with better gastrointestinal tolerability and 
less metallic taste. Bacterial vaginosis is associated with high rates of recurrence and appropri-
ate management of such recurrences can prove difficult. Recurrent BV has been linked with 
persistence of Gardnerella vaginalis after treatment; however the clinical implications of the 
possible greater activity of tinidazole against G. vaginalis are not yet clear. Repeated courses 
of oral metronidazole may be poorly tolerated and an alternative but equally effective treatment 
that is better tolerated may be preferable. In comparison to oral metronidazole, cost is clearly 
an issue as oral metronidazole is considerably cheaper and available in generic form. However 
where avoidance of oral metronidazole is necessary because of side effects, oral tinidazole is 
a cost-effective alternative.
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Introduction
Bacterial vaginosis (BV) is the commonest cause of vaginal discharge in women of 
childbearing age. It is characterized by a thin homogenous white discharge, a vaginal 
pH of greater than 4.5, a positive amine test and the presence of clue cells microscopi-
cally. There is a change from the normal lactobacilli (LB) dominant vaginal flora, 
with hydrogen peroxide production, to flora with greatly reduced numbers of LB and 
an increase in the concentration and prevalence of organisms including Gardnerella 
vaginalis, Mycoplasma hominis and anaerobic bacteria such as peptostretococci, 
Prevotella spp., and Mobiluncus spp.1 Recently Atopobium vaginae, and some non-
culturable species identified by molecular analysis (named BV associated bacteria 
[BVAB]), have also been found in association with BV.2,3
The diagnosis of bacterial vaginosis can be made using the Amsel’s clinical criteria.4 
Three of the following should be present: thin homogenous white discharge, vaginal International Journal of Women’s Health 2009:1 60
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pH greater than 4.5, amine odor after adding 10% potassium 
hydroxide to vaginal fluid, and clue cells on microscopy 
(at least 1 in 5 vaginal epithelial cells). Alternatively a vaginal 
smear can be Gram-stained and scored microscopically as 
according to Nugent.5 The scoring is between 0 and 10 based 
on the relative quantities of various bacteria. Scores of 7 to 10 
are consistent with BV, 4 to 6 indicate intermediate flora and 
0 to 3 are normal flora.
The pathogenesis of BV is not yet clearly understood. 
BV has been associated with a number of complications 
including risk of late miscarriage and preterm birth,6 postoper-
ative infections including postabortion-PID, posthysterectomy 
cuff cellulitis and postCesarean endometritis,7 and possibly 
pelvic inflammatory disease (PID).8 It has also been associated 
with an increased risk of acquiring HIV-1 infection.9,10
Oral metronidazole has long been established as an 
effective therapy in the treatment of BV. Intravaginal 
preparations of metronidazole and clindamycin have 
also been widely used. In 1999 Joesoef et al updated 
their previous publication which had reviewed treatment 
options for BV.11,12 The additional published studies on 
the treatment of bacterial vaginosis from 1993 through to 
1996 were reviewed. Their first-line recommended treat-
ments in nonpregnant women were oral metronidazole 
500 mg twice daily for 7 days, or clindamycin vagi-
nal cream 2% once daily for 7 days, or metronidazole 
vaginal gel 0.75% twice daily for 5 days. There were no 
statistically significant differences in cumulative cure 
rates between these treatments. Their previous paper had 
identified that the 7-day regimen of oral metronidazole 
was more efficacious than the single dose regimen of 2 g 
of metronidazole (the cumulative cure rates 3 to 4 weeks 
after completion of treatment were 82% vs 62%).11
However, adverse effects due to metronidazole are 
frequent,13 and this may lead to problems with adherence to 
a 7-day course of treatment and subsequently result in treat-
ment failure. Consequently, other drugs of the nitroimidazole 
class have been explored as alternatives to metronidazole for 
the treatment of BV.
Tinidazole, 1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-
nitroimidazole, was first introduced into clinical medi-
cine in 1967 for the treatment of Trichomonas vaginalis 
infections.14 It has subsequently been used for the treatment 
of other protazoal infections including giardiasis and 
amoebiasis, in the eradication of Helicobacter pylori 
infection, and in anaerobic infections such as intraperitoneal 
infections, postoperative wound infections, skin and soft 
tissue infections and gynecological infections including BV. 
Here we review both the pharmacological profile of tinidazole 
and the evidence for its efficacy in the treatment of BV.
Mechanism of action, 
pharmacokinetics and metabolism
Tinidazole is a prodrug that is converted to cytotoxic forms 
in vivo. It has a low molecular weight and penetrates the cell 
membrane of both aerobic and anaerobic microorganisms. 
After diffusing into the cells of susceptible organisms, tinida-
zole is reduced at its nitro group to short lived toxic radicals 
by a ferridoxin-mediated transport system. It is thought that 
these toxic intermediates bind to DNA resulting in DNA 
damage which ultimately leads to cell death.15 Most aerobic 
bacteria are unable to generate the toxic radicals and are thus 
not susceptible to tinidazole.
A pharmacokinetic comparison of oral tinidazole 500 mg 
and oral metronidazole 500 mg showed tinidazole to a have 
a significantly higher Cmax, area under the curve, and longer 
half-life.16 Both drugs achieve good tissue levels in the 
female reproductive tract at 70% to 100% of those of the 
simultaneous serum levels. However, the steady-state serum 
concentration of tinidazole following oral administration was 
higher than that of metronidazole.17 The half-life of tinidazole 
is 12.7 hours and the antimicrobial plasma concentrations 
maintained in the tissues are sufficient to permit once daily 
dosing. The pharmacokinetic properties are similar after 
oral doses of 2000 mg and intravenous doses of 800 mg 
and 1600 mg. It is minimally bound to plasma protein (12%) 
and is widely distributed in all body tissues.
Elimination is primarily by hepatic metabolism (approxi-
mately 63%). Due to lack of data, use of tinidazole in patients 
with severe hepatic impairment is not recommended. No 
adjustment of the tinidazole dosage appears to be necessary 
based on renal function.18
In vitro activity
Tinidazole is active against anaerobic protozoa including 
T. vaginalis, E histolytica and G lamblia. It also has in 
vitro activity against most anaerobic bacteria including 
Bacteriodes, Fusobacterium and Clostridium spp.18 Two 
comparative in vitro studies showed minor enhanced in vitro 
activity against G. vaginalis with tinidazole compared to 
metronidazole.19,20 More recently, antimicrobial susceptibility 
testing to metronidazole and tinidazole was performed on 
470 vaginal isolates from women with bacterial vaginosis.21 
The overall spectrum of activity against the BV-associated 
bacteria was very similar. Lactobacillus isolates were the 
least susceptible to tinidazole and metronidazole with 96% International Journal of Women’s Health 2009:1 61
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and 100% of Lactobacillus isolates showing resistance. This 
was expected as facultative organisms are generally not 
inhibited by nitroimidazoles because the reduction of the 
nitro group is dependent upon the absence of oxygen. Of the 
G. vaginalis isolates 54% and 68% were resistant to tinida-
zole and metronidazole respectively. 15% of the G vaginalis 
isolates were resistant to metronidazole but susceptible 
to tinidazole, whereas only one isolate was susceptible 
to metronidazole and resistant to tinidazole (P = 0.001). 
Tinidazole therefore shows activity against anaerobes 
similar to that of metronidazole with slightly greater activity 
against G. vaginalis. Mobiluncus spp. are resistant to both 
metronidazole and tinidazole with similar MICs.22 Atopobium 
vaginae also appears to be highly resistant to metronidazole, 
but susceptibility testing to tinidazole was not performed.2 
There are no efficacy data against the newly identified non-
culturable bacteria associated with BV.
Studies of tinidazole and BV
Oral tinidazole has been used to treat bacterial vaginosis for 
over 25 years but in a number of different dosage regimens. 
There have been a number of published clinical studies but 
unfortunately there are several problems in trying to compare 
and evaluate these trials. Many were carried out prior to the 
universally recognized diagnostic clinical criteria of Amsel4 
and the Nugent Gram stain score 5 and before the use of the 
term ‘bacterial vaginosis’ was introduced when the condition 
was known as non specific vaginitis. Furthermore there are 
differences in the dosing and duration of tinidazole used, 
ranging from 1 to 2 g daily for 1 to 5 days, and also in the 
comparator drug.
Comparison of treatment trials for BV has been 
recognized as being complex. In 1992 Larsson reviewed 
treatments of bacterial vaginosis.23 He cited the following 
differences between treatment studies: the criteria used for 
the diagnosis of BV vary; different exclusion criteria are 
used; the definition of cure varies; the timing of treatment 
evaluation varies; and some studies are double-blind placebo 
controlled trials whereas others are open trials.23 In order to 
try to overcome these differences, in 1998, the FDA issued 
a draft guidance document entitled “Bacterial Vaginosis – 
Developing Antimicrobial Drugs for Treatment”.24 This 
called for investigators to define BV in study participants 
as the presence of all four of Amsel’s criteria plus a 
Nugent score of 7 to 10, and to perform the examination 
for evaluation of therapeutic response at 21to 30 days after 
the first few days of treatment. It recommended that cure 
should be defined as absence of all four Amsel’s criteria plus 
a Nugent score of 0 to 3. While these recommendations may 
ensure uniformity amongst trial evaluations, such a strict 
definition of cure may not necessarily identify differences 
between treatment efficacies. An example of variation in 
treatment results using the different methods of evaluation 
was shown in a comparison of two intravaginal metroni-
dazole regimens for the treatment of BV.25 The authors 
observed a significant difference between the two regimens 
at follow up when BV was defined by the presence of at least 
three of four Amsel’s criteria, or a Nugent score of 7 to 10, 
or both. However, no significant difference in rates of cure 
was found using the 1998 FDA draft guidance definition of 
cure.25 Only the most recently published study comparing 
two different doses of tinidazole to treat BV has used the 
FDA definition of cure.26
Although comparison between different treatment studies 
is difficult, placebo controlled trials have consistently shown 
increases in cure rate with tinidazole (see Table 1).26–30 The 
cure rates with tinidazole ranged from 46% to 71% for 
tinidazole 2 g oral single dose, 74% for 2 g daily for 2 days 
and 91% for the 1 g daily for 5 days dose.27–30 Comparative 
studies suggest that oral tinidazole is equivalent to oral 
metronidazole,20,31–35 intravaginal clindamycin cream,33,35 
and intravaginal metronidazole tablets,36 in efficacy in treat-
ing BV. There are no data comparing oral tinidazole with 
intravaginal metronidazole gel.
In 2007 Nailor and Sobel reviewed 21 clinical efficacy 
studies evaluating tinidazole for bacterial vaginosis.37 They 
concluded that compared with placebo, tinidazole in all 
studied regimens consistently demonstrated at least short 
term efficacy in eradicating signs and symptoms of BV. 
Tinidazole 2 g/day (single daily dose) for 2 days appeared 
more effective than a single tinidazole 2 g dose (1 day 
dose). A lower daily dose (500 mg twice daily or 1 g once 
daily) taken for a longer period, for example 5 days, was 
also highly effective.37 Following that review, Livengood 
et al26 published the results of a randomized controlled trial 
assessing the effectiveness of tinidazole orally 1 g once 
daily for 5 days and 2 g once daily for 2 days, compared 
with placebo, in the treatment of bacterial vaginosis. 
Follow up was at 21 to 30 days after treatment, using the 
strict FDA recommended criteria to define cure. Cure 
rates were 36.8% for the 1 g daily for 5 days regimen, 
27.4% for the 2 g daily for 2 days regimen and 5.1% for 
the placebo group. They concluded that both regimens 
gave significantly higher cure rates than placebo and are 
an effective treatment for BV. The 1 g once daily for 
5 days regimen showed trends toward better efficacy and International Journal of Women’s Health 2009:1 62
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tolerability than the 2 g once daily for 2 days regimen but 
this was not statistically significant.26
Whether or not tinidazole has better efficacy than 
metronidazole is currently impossible to say. When the 
same drug dose and duration have been compared (ie, 2 g 
single day dose) tinidazole has had higher cure rates than 
metronidazole.20,35 However, it is now recognized that single 
dose oral therapy is not as effective as a longer course and 
metronidazole 2 g single dose is no longer recommended as 
first-line therapy for BV.11,38 There has been no published 
head-to-head comparison of the more effective oral 
metronidazole regimen (500 mg twice daily for 7 days) with 
the more effective tinidazole regimen (1 g daily for 5 days). 
Such a study is needed to clarify if there are any differences 
in cure rates of BV between the two treatments.
Recurrences of bacterial vaginosis are frequent and 
appropriate management can prove difficult.1 Persistence of 
G. vaginalis,39 Atopodium vaginae,39 Mobiluncus curtisii,40 
and the BVAB41 after treatment has been linked with 
recurrences of BV. Both metronidazole and tinidazole appear 
to be ineffective against M. curtisii, however the clinical 
implications of the possible greater activity of tinidazole 
against G. vaginalis are not yet clear.21 Repeated courses of 
oral metronidazole may be poorly tolerated and an alternative 
equally effective treatment that is better tolerated may be 
preferable.
Current recommended  
use of tinidazole
The 2006 UK National Guidelines for the management of 
bacterial vaginosis currently recommend oral metronidazole 
as first-line treatment with tinidazole 2 g single oral dose as 
an alternative.42 The 2004 Australasian College of Sexual 
Health Physicians Clinical Guidelines for the management of 
sexually transmissible infections among priority populations 
list tinidazole 2 g single oral dose for the treatment of 
bacterial vaginosis but caution that the cure rate may be 
lower than a longer course of treatment.43
Table 1 Clinical studies evaluation efficacy of tinidazole for bacterial vaginosis
Reference No. in study Tinidazole cure rate (%) Comparators, doses and cure rates (%) Ref
Metronidazole Placebo Other
2 g (and 1 g bid) studies
Paavonen 198327 33 71 38 27
van der Meiden 198329 26 46 8 29
ekgren 198830 247 51 4 74 (tinidazole 2 g × 2 days) 30
Mohanty 198720 280 92 79 (2 g) 88 (nimorazole) 20
Milani 200335 89 88 73 (2 g) 35
Sanz-Sanz 198531 (1 g bid) 80 65 74 (500 mg bid × 7 days) 31
Buranawarodomkul 199032 100 86 92 (500 mg bid × 7 days) 32
Sanz-Sanz 199633 230 75 80 (500 mg bid × 7 days) 85 (ciprofloxacin  
500 mg bid × 3 days)  
85 (clindamycin vaginal 
cream 2% × 7 days)
33
Milani 200334 64 94 77 (clindamycin vaginal 
cream 2% × 7 days)
34
Schindler 199136 75 84 82 (400 mg bid × 5 days 
intravaginal tablet)
36
2 g × 2-day or 2 g × 3-day studies (or 1 g bid × 2 or 3 days)
Sanz-Sanz 198531 60 50 (1 g bid × 2 days) 63 (ornidazole  
1 g bid × 2 days)
31
ekgren 198830 247 74 (2 g × 2 days) 4 51 (tinidazole 2 g) 30
Livengood 200726 235 27.4 (2 g × 2 days) 5.1 26
1 g × 5-day studies
Piot 198328  
(500 mg bid × 5 days)
57 91 40 44 (intravaginal,  
sulfa bid × 7 days)
28
Livengood 200726 235 36.8 5.1 26International Journal of Women’s Health 2009:1 63
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The 2001 European,44 the 2003 WHO,45 the 2006 US,38 
and the 2008 Canadian46 guidelines do not include tinidazole 
as a preferred or alternative option in the treatment of 
bacterial vaginosis. Of note is that the US Food and Drug 
Administration (FDA) only approved tinidazole for the 
treatment of bacterial vaginosis in May 2007 based on 
the results of the Livengood study.26 This approval was after 
the publication of the current 2006 sexually transmitted 
diseases treatment guidelines.
Safety and tolerability
There is substantial information regarding the tolerability 
of tinidazole and its safety profile. It seems to be free 
from clinical toxicity following standard oral and 
intravenous doses. Apte and Packard evaluated the safety 
of tinidazole in 1517 adult and pediatric patients.47 Of 
these, 143 patients (9.4%) experienced one or more 
adverse event. The most frequently encountered adverse 
events were nausea (3.6%), abdominal discomfort (2.4%), 
vomiting (1.7%), anorexia (1.3%), constipation (1.2%), 
headache (0.9%), and a dry mouth (0.6%).47 An analysis 
of the results of 5 randomized controlled trials comparing 
tinidazole with metronidazole for the treatment of 
99 patients with confirmed amoebic liver abscess reported 
gastrointestinal adverse events in 6% of patients receiving 
tinidazole and 41% of patients receiving metronidazole.48 
Patients who received metronidazole experienced 
significantly more nausea (36.7% with metronidazole 
versus 6.0% with tinidazole; P  0.01), anorexia (28.6% 
versus 4.0%; P  0.01), vomiting (24.4% versus 0%) and 
metallic taste (18.4% versus 0%).48
Adverse events associated with tinidazole are usually 
mild and self-limiting. Hypersensitivity reactions have 
however been reported, presenting as angioedema, periorbital 
and laryngeal edema, bronchospasm, dyspnea, fixed drug 
eruptions and generalized urticaria. There have been reports 
of peripheral neuropathy and convulsions associated with 
metronidazole use, so it is recommended that tinidazole 
should be used with caution in patients with central nervous 
system syndromes and abnormalities.15
Tinidazole crosses the placental barrier. Since the 
effects of compounds of this class on fetal development 
are unknown, the manufacturers recommend avoidance 
during the first trimester. There is no evidence that it 
is harmful during the latter stages of pregnancy, but 
its use during the second and third trimesters requires 
the potential benefits be weighed against possible 
hazards  to  mother  or  fetus  (Summary  of  Product 
Characteristics [SPC] Fasigyn®; Pfizer Ltd, Ramsgate 
Road, Sandwich, Kent, UK).
Interactions
Like metronidazole, concurrent use of tinidazole with 
alcohol may produce a disulfram-like reaction and should 
be avoided. Drugs of similar chemical structure have been 
shown to potentiate the effects of oral anticoagulants and 
it is advised that prothombin time be monitored closely 
(SPC). Co-administration of lithium and metronidazole 
may increase the risk of lithium toxicity. It is not known if 
this interaction occurs with other nitroimidazoles but close 
monitoring of lithium levels would be advised when given 
with tinidazole.
Cost
Oral metronidazole is the least expensive of all established 
treatments for bacterial vaginosis. The British National 
Formulary quotes the current UK price49 as £1.29 for a 
21-tablet pack of 400 mg tablets. Metronidazole 0.75% 
intravaginal gel 40 g pack costs £4.31 compared to £10.86 
for clindamycin 2% intravaginal cream 40 g pack. Oral 
tinidazole has a price of £13.80 for a 20-tablet pack of 500 mg 
tablets meaning a 2 g single dose costs £2.76 and 1 g daily 
for 5 days regimen costs £6.90 (see Table 2). Therefore, if an 
alternative to oral metronidazole is required, oral tinidazole 
compares favorably in terms of cost with both metronidazole 
and clindamycin intravaginal preparations.
Table 2 Approximate costs of treatment regimens for bacterial vaginosis from British National Formulary March 200949
Drug Dose and duration Cost (£)
Oral metronidazole 400 mg/500 mg twice daily for 7 days 0.86
Oral metronidazole 2 g single dose 0.31
Metronidazole 0.75% intravaginal gel, 40 g pack 5 g applicator per night for 5 nights 4.31
Clindamycin 2% intravaginal cream, 40 g pack 5 g applicator per night for 7 nights 10.86
Oral tinidazole 1 g daily for 5 days 6.90
Oral tinidazole 2 g single dose 2.76International Journal of Women’s Health 2009:1 64
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Conclusion
Tinidazole shows proven efficacy in the treatment of BV. 
The cure rates are comparable to those of metronidazole, 
but clinical superiority has not been demonstrated. However, 
tinidazole has a more favorable side effect profile, notably 
with better gastrointestinal tolerability and less metallic 
taste, both of which are often implicated in poor adherence 
to metronidazole therapy. Comparative studies suggest that 
oral tinidazole is equivalent to intravaginal clindamycin 
cream and intravaginal metronidazole tablets in efficacy 
in the treatment of BV. The optimal dose and duration of 
tinidazole has not been established but it appears that longer 
courses are better than single day therapy.
Bacterial vaginosis is associated with high rates of 
recurrence and appropriate management of such recurrences 
can prove difficult. Recurrent BV has been linked with 
persistence of G. vaginalis after treatment; however the 
clinical implications of the possible greater activity of 
tinidazole against G. vaginalis are not yet clear. Repeated 
courses of oral metronidazole may be poorly tolerated and 
an alternative but equally effective treatment that is better 
tolerated may be preferable.
In comparison to oral metronidazole, cost is clearly an 
issue as metronidazole is considerably cheaper and available 
in generic form. However where avoidance of oral metroni-
dazole is necessary because of side effects, oral tinidazole 
is a cost-effective alternative.
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